TY - GEN AU - Venketaraman,Vishwanath AU - Venketaraman,Vishwanath TI - Host-Directed Therapies for Tuberculosis SN - books978-3-03943-502-9 PY - 2020/// CY - Basel, Switzerland PB - MDPI - Multidisciplinary Digital Publishing Institute KW - Research & information: general KW - bicssc KW - Biology, life sciences KW - Mycobacterium tuberculosis KW - host-directed therapies KW - immune responses KW - tuberculosis KW - lung cancer KW - misdiagnosis KW - invasive procedure KW - revising KW - antiplatelet KW - aspirin KW - immunomodulation KW - survival KW - Taiwan KW - latent infection KW - pulmonary KW - rabbit KW - iron supplementation KW - pathology KW - immune response KW - gene expression KW - Perls’ stain KW - autophagy KW - M. tb KW - BCG vaccination KW - immune exhaustion KW - glutathione KW - cytokines KW - granulomas KW - type 2 diabetes KW - co-morbidities KW - co-infections KW - inflammation KW - redox imbalance KW - antioxidants N1 - Open Access N2 - TB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB UR - https://mdpi.com/books/pdfview/book/3102 UR - https://directory.doabooks.org/handle/20.500.12854/69310 ER -